Neoadjuvant Intra-Arterial Cytoreductive Chemotherapy for Lacrimal Gland Adenoid Cystic Carcinoma: A Long-Term Follow-up Study of a Trimodal Strategy
To report the therapeutic efficacy of integrating neoadjuvant chemotherapy with conventional bimodal therapies for lacrimal gland adenoid cystic carcinoma by providing an additional 8 years of follow-up data on the same cohort of patients whose cumulative 10-year disease-free survival outcomes were...
Uloženo v:
| Vydáno v: | American journal of ophthalmology Ročník 240; s. 239 - 251 |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
Elsevier Inc
01.08.2022
Elsevier Limited |
| Témata: | |
| ISSN: | 0002-9394, 1879-1891, 1879-1891 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | To report the therapeutic efficacy of integrating neoadjuvant chemotherapy with conventional bimodal therapies for lacrimal gland adenoid cystic carcinoma by providing an additional 8 years of follow-up data on the same cohort of patients whose cumulative 10-year disease-free survival outcomes were reported in 2013.
Non-randomized, retrospective, interventional case series.
Nineteen consecutive patients treated with neoadjuvant intra-arterial cytoreductive chemotherapy (IACC), orbital exenteration, chemoradiotherapy, and adjuvant intravenous chemotherapy at a single institution were included. Analyses were undertaken of locoregional recurrences and distant metastases, disease-free survival time, TNM tumor stage at presentation, response to IACC, and prognostic impact of positive resection margins. The main outcome measures were overall survival, disease-free survival, disease relapse, positive tumor resection margins, and tumor stage at presentation.
Eight patients with an intact lacrimal artery (group 1), 7 with AJCC stage T4a-c, had significantly better overall survival (87.5% versus 14.3% at 15 years), disease-specific mortality, and recurrences (all < .001, log-rank test) than prior conventionally treated patients from the Bascom Palmer Eye Institute. Group 1 was superior to group 2, patients lacking an intact lacrimal artery, concerning overall survival (P = .042) and recurrence (P = .017), but with no significant difference in disease-specific mortality (P = .23). Group 2 was associated with a significantly lower cause-specific mortality than the institutional comparator group (P = .039). Prior tumor resection with lateral wall osteotomy and failure to adhere to all protocol elements were adverse prognostic factors for suboptimal outcomes. Positive tumor margins increased the risk of all-cause mortality 4.1 times (P = .036, stratified Cox proportional hazards regression) and disease-specific mortality 8.0 times (P = .043, stratified Cox proportional hazards regression) than a patient with negative margins.
Extended follow-up supplemented with AJCC staging data supports neoadjuvant IACC as an integral component of a trimodal treatment strategy in patients with an intact lacrimal artery. Protocol elements implemented as designed appear to have improved overall survival and decreased disease relapse in this cohort. This extended long-term IACC dataset suggests that a critical bar of at least 15 years of follow-up is appropriate for assessing the efficacy of current conventional and future globe-sparing bimodal therapies. |
|---|---|
| AbstractList | To report the therapeutic efficacy of integrating neoadjuvant chemotherapy with conventional bimodal therapies for lacrimal gland adenoid cystic carcinoma by providing an additional 8 years of follow-up data on the same cohort of patients whose cumulative 10-year disease-free survival outcomes were reported in 2013.
Non-randomized, retrospective, interventional case series.
Nineteen consecutive patients treated with neoadjuvant intra-arterial cytoreductive chemotherapy (IACC), orbital exenteration, chemoradiotherapy, and adjuvant intravenous chemotherapy at a single institution were included. Analyses were undertaken of locoregional recurrences and distant metastases, disease-free survival time, TNM tumor stage at presentation, response to IACC, and prognostic impact of positive resection margins. The main outcome measures were overall survival, disease-free survival, disease relapse, positive tumor resection margins, and tumor stage at presentation.
Eight patients with an intact lacrimal artery (group 1), 7 with AJCC stage T4a-c, had significantly better overall survival (87.5% versus 14.3% at 15 years), disease-specific mortality, and recurrences (all < .001, log-rank test) than prior conventionally treated patients from the Bascom Palmer Eye Institute. Group 1 was superior to group 2, patients lacking an intact lacrimal artery, concerning overall survival (P = .042) and recurrence (P = .017), but with no significant difference in disease-specific mortality (P = .23). Group 2 was associated with a significantly lower cause-specific mortality than the institutional comparator group (P = .039). Prior tumor resection with lateral wall osteotomy and failure to adhere to all protocol elements were adverse prognostic factors for suboptimal outcomes. Positive tumor margins increased the risk of all-cause mortality 4.1 times (P = .036, stratified Cox proportional hazards regression) and disease-specific mortality 8.0 times (P = .043, stratified Cox proportional hazards regression) than a patient with negative margins.
Extended follow-up supplemented with AJCC staging data supports neoadjuvant IACC as an integral component of a trimodal treatment strategy in patients with an intact lacrimal artery. Protocol elements implemented as designed appear to have improved overall survival and decreased disease relapse in this cohort. This extended long-term IACC dataset suggests that a critical bar of at least 15 years of follow-up is appropriate for assessing the efficacy of current conventional and future globe-sparing bimodal therapies. To report the therapeutic efficacy of integrating neoadjuvant chemotherapy with conventional bimodal therapies for lacrimal gland adenoid cystic carcinoma by providing an additional 8 years of follow-up data on the same cohort of patients whose cumulative 10-year disease-free survival outcomes were reported in 2013.PURPOSETo report the therapeutic efficacy of integrating neoadjuvant chemotherapy with conventional bimodal therapies for lacrimal gland adenoid cystic carcinoma by providing an additional 8 years of follow-up data on the same cohort of patients whose cumulative 10-year disease-free survival outcomes were reported in 2013.Non-randomized, retrospective, interventional case series.DESIGNNon-randomized, retrospective, interventional case series.Nineteen consecutive patients treated with neoadjuvant intra-arterial cytoreductive chemotherapy (IACC), orbital exenteration, chemoradiotherapy, and adjuvant intravenous chemotherapy at a single institution were included. Analyses were undertaken of locoregional recurrences and distant metastases, disease-free survival time, TNM tumor stage at presentation, response to IACC, and prognostic impact of positive resection margins. The main outcome measures were overall survival, disease-free survival, disease relapse, positive tumor resection margins, and tumor stage at presentation.METHODSNineteen consecutive patients treated with neoadjuvant intra-arterial cytoreductive chemotherapy (IACC), orbital exenteration, chemoradiotherapy, and adjuvant intravenous chemotherapy at a single institution were included. Analyses were undertaken of locoregional recurrences and distant metastases, disease-free survival time, TNM tumor stage at presentation, response to IACC, and prognostic impact of positive resection margins. The main outcome measures were overall survival, disease-free survival, disease relapse, positive tumor resection margins, and tumor stage at presentation.Eight patients with an intact lacrimal artery (group 1), 7 with AJCC stage T4a-c, had significantly better overall survival (87.5% versus 14.3% at 15 years), disease-specific mortality, and recurrences (all < .001, log-rank test) than prior conventionally treated patients from the Bascom Palmer Eye Institute. Group 1 was superior to group 2, patients lacking an intact lacrimal artery, concerning overall survival (P = .042) and recurrence (P = .017), but with no significant difference in disease-specific mortality (P = .23). Group 2 was associated with a significantly lower cause-specific mortality than the institutional comparator group (P = .039). Prior tumor resection with lateral wall osteotomy and failure to adhere to all protocol elements were adverse prognostic factors for suboptimal outcomes. Positive tumor margins increased the risk of all-cause mortality 4.1 times (P = .036, stratified Cox proportional hazards regression) and disease-specific mortality 8.0 times (P = .043, stratified Cox proportional hazards regression) than a patient with negative margins.RESULTSEight patients with an intact lacrimal artery (group 1), 7 with AJCC stage T4a-c, had significantly better overall survival (87.5% versus 14.3% at 15 years), disease-specific mortality, and recurrences (all < .001, log-rank test) than prior conventionally treated patients from the Bascom Palmer Eye Institute. Group 1 was superior to group 2, patients lacking an intact lacrimal artery, concerning overall survival (P = .042) and recurrence (P = .017), but with no significant difference in disease-specific mortality (P = .23). Group 2 was associated with a significantly lower cause-specific mortality than the institutional comparator group (P = .039). Prior tumor resection with lateral wall osteotomy and failure to adhere to all protocol elements were adverse prognostic factors for suboptimal outcomes. Positive tumor margins increased the risk of all-cause mortality 4.1 times (P = .036, stratified Cox proportional hazards regression) and disease-specific mortality 8.0 times (P = .043, stratified Cox proportional hazards regression) than a patient with negative margins.Extended follow-up supplemented with AJCC staging data supports neoadjuvant IACC as an integral component of a trimodal treatment strategy in patients with an intact lacrimal artery. Protocol elements implemented as designed appear to have improved overall survival and decreased disease relapse in this cohort. This extended long-term IACC dataset suggests that a critical bar of at least 15 years of follow-up is appropriate for assessing the efficacy of current conventional and future globe-sparing bimodal therapies.CONCLUSIONSExtended follow-up supplemented with AJCC staging data supports neoadjuvant IACC as an integral component of a trimodal treatment strategy in patients with an intact lacrimal artery. Protocol elements implemented as designed appear to have improved overall survival and decreased disease relapse in this cohort. This extended long-term IACC dataset suggests that a critical bar of at least 15 years of follow-up is appropriate for assessing the efficacy of current conventional and future globe-sparing bimodal therapies. PurposeTo report the therapeutic efficacy of integrating neoadjuvant chemotherapy with conventional bimodal therapies for lacrimal gland adenoid cystic carcinoma by providing an additional 8 years of follow-up data on the same cohort of patients whose cumulative 10-year disease-free survival outcomes were reported in 2013.DesignNon-randomized, retrospective, interventional case series.MethodsNineteen consecutive patients treated with neoadjuvant intra-arterial cytoreductive chemotherapy (IACC), orbital exenteration, chemoradiotherapy, and adjuvant intravenous chemotherapy at a single institution were included. Analyses were undertaken of locoregional recurrences and distant metastases, disease-free survival time, TNM tumor stage at presentation, response to IACC, and prognostic impact of positive resection margins. The main outcome measures were overall survival, disease-free survival, disease relapse, positive tumor resection margins, and tumor stage at presentation.ResultsEight patients with an intact lacrimal artery (group 1), 7 with AJCC stage T4a-c, had significantly better overall survival (87.5% versus 14.3% at 15 years), disease-specific mortality, and recurrences (all < .001, log-rank test) than prior conventionally treated patients from the Bascom Palmer Eye Institute. Group 1 was superior to group 2, patients lacking an intact lacrimal artery, concerning overall survival (P = .042) and recurrence (P = .017), but with no significant difference in disease-specific mortality (P = .23). Group 2 was associated with a significantly lower cause-specific mortality than the institutional comparator group (P = .039). Prior tumor resection with lateral wall osteotomy and failure to adhere to all protocol elements were adverse prognostic factors for suboptimal outcomes. Positive tumor margins increased the risk of all-cause mortality 4.1 times (P = .036, stratified Cox proportional hazards regression) and disease-specific mortality 8.0 times (P = .043, stratified Cox proportional hazards regression) than a patient with negative margins.ConclusionsExtended follow-up supplemented with AJCC staging data supports neoadjuvant IACC as an integral component of a trimodal treatment strategy in patients with an intact lacrimal artery. Protocol elements implemented as designed appear to have improved overall survival and decreased disease relapse in this cohort. This extended long-term IACC dataset suggests that a critical bar of at least 15 years of follow-up is appropriate for assessing the efficacy of current conventional and future globe-sparing bimodal therapies. |
| Author | Tse, David T. Tse, Brian C. Feuer, William J. Benedetto, Pasquale W. |
| Author_xml | – sequence: 1 givenname: David T. surname: Tse fullname: Tse, David T. email: dtse@med.miami.edu organization: From Dr. Nasser Ibrahim Al-Rashid Orbital Vision Research Center. Bascom Palmer Eye Institute, Department of Ophthalmology (D.T.T, B.C.T, W.J.F), University of Miami Miller School of Medicine, Miami, FL, USA – sequence: 2 givenname: Pasquale W. surname: Benedetto fullname: Benedetto, Pasquale W. organization: Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA (P.W.B) – sequence: 3 givenname: Brian C. orcidid: 0000-0002-2270-9219 surname: Tse fullname: Tse, Brian C. organization: From Dr. Nasser Ibrahim Al-Rashid Orbital Vision Research Center. Bascom Palmer Eye Institute, Department of Ophthalmology (D.T.T, B.C.T, W.J.F), University of Miami Miller School of Medicine, Miami, FL, USA – sequence: 4 givenname: William J. surname: Feuer fullname: Feuer, William J. organization: From Dr. Nasser Ibrahim Al-Rashid Orbital Vision Research Center. Bascom Palmer Eye Institute, Department of Ophthalmology (D.T.T, B.C.T, W.J.F), University of Miami Miller School of Medicine, Miami, FL, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35381201$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFUs2O0zAYjNAi9gcegAuyxIVLiv-axCCtVFXsslIFhy1ny7G_tA6JXRynKA_C--Kqywp6WE6W5ZnxN_PNZXbmvIMse03wjGBSvG9nqvUziimdYTbDtHyWXZCqFDmpBDnLLjDGNBdM8PPschjadC1KXr7IztmcVYRicpH9-gJemXbcKxfRnYtB5YsQIVjVoeUUfQAz6mj3gJZb6H3cQlC7CTU-oJXSwfYJd9spZ9DCgPPWJNYQrUZLFbR1vlcf0AKtvNvkawg9uvFd53_m4w7dx9FMyDdIoXXS8SYp3af_I2yml9nzRnUDvHo4r7JvN5_Wy8_56uvt3XKxyvWcipiLSvG5KUAbw5q6app5XaRcKqVp2RAuGuAkWeWVrqnmmJcK10I1YChjRY0Nu8quj7q7se7BaDgE0MndwVeYpFdW_vvi7FZu_F6mUAtByiTw7kEg-B8jDFH2dtDQpUTAj4OkBS-LOaesStC3J9DWj8ElewklCGcV5Tih3vw90eMofzaWAOQI0MEPQ4DmEUKwPLRCtjK1Qh5aITGTqRWJU55wtI0qWn8wZbsnmR-PTEhb2FsIctAWnAZjA-gojbdPssUJW3fWWa267zD9h_sb-AjnBA |
| CitedBy_id | crossref_primary_10_4103_joco_joco_231_23 crossref_primary_10_1227_ons_0000000000001609 crossref_primary_10_3390_cancers15123211 crossref_primary_10_1002_hed_28121 crossref_primary_10_1016_j_heliyon_2024_e33889 crossref_primary_10_1186_s12885_025_13438_z crossref_primary_10_1097_IOP_0000000000002881 crossref_primary_10_1177_11206721241249503 crossref_primary_10_1002_cam4_6831 crossref_primary_10_1097_IOP_0000000000003029 crossref_primary_10_1136_bjo_2025_327745 crossref_primary_10_1097_IOP_0000000000002548 |
| Cites_doi | 10.1001/archopht.116.3.315 10.1016/j.ophtha.2008.12.049 10.1016/S0046-8177(82)80180-9 10.1038/bjc.1977.1 10.18632/oncotarget.26558 10.1097/00004397-198202210-00009 10.1158/0008-5472.CAN-15-1370 10.1016/S1470-2045(05)70023-1 10.1016/0002-9610(84)90384-2 10.1016/j.ophtha.2013.05.006 10.1016/j.ajo.2005.08.070 10.1016/j.ajo.2005.08.068 10.1001/archopht.116.5.613 10.1016/0002-9394(75)90455-9 10.1097/01.IOP.0000105518.72611.4F 10.1016/j.ophtha.2013.11.012 10.1016/0002-9394(76)90068-4 10.1136/bmj.d6395 10.1097/00004397-196206000-00005 10.1136/bjo.76.7.401 10.1002/cncr.26740 10.2214/AJR.11.7420 10.1097/01.iop.0000232164.00208.b4 10.1016/j.ajo.2018.07.024 10.1016/j.ejso.2007.11.001 10.1097/IOP.0000000000000877 10.1097/00006534-198110000-00017 10.1093/jnci/88.19.1346 10.1136/bjo.70.10.727 10.1016/S0161-6420(85)34081-2 10.1097/IOP.0000000000001177 10.1038/onc.2011.384 10.1016/j.ophtha.2013.01.027 10.1200/JCO.1998.16.1.309 10.1097/00002341-199403000-00009 10.1136/bmj.d6397 10.1136/bjo.63.9.600 |
| ContentType | Journal Article |
| Copyright | 2022 Elsevier Inc. Copyright © 2022 Elsevier Inc. All rights reserved. 2022. Elsevier Inc. |
| Copyright_xml | – notice: 2022 Elsevier Inc. – notice: Copyright © 2022 Elsevier Inc. All rights reserved. – notice: 2022. Elsevier Inc. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM K9. NAPCQ 7X8 5PM |
| DOI | 10.1016/j.ajo.2022.03.027 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic ProQuest Health & Medical Complete (Alumni) |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1879-1891 |
| EndPage | 251 |
| ExternalDocumentID | PMC9396917 35381201 10_1016_j_ajo_2022_03_027 S0002939422001362 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NEI NIH HHS grantid: P30 EY014801 |
| GroupedDBID | --- --K --M -~X .1- .55 .FO .GJ .~1 0R~ 1B1 1CY 1P~ 1~. 1~5 23M 4.4 457 4G. 53G 5GY 5RE 5VS 6J9 7-5 71M 8P~ AABNK AAEDT AAEDW AAHTB AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABCQX ABDPE ABFNM ABFRF ABJNI ABLJU ABMAC ABMZM ABOCM ABPEJ ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACIUM ACLOT ACNCT ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADFRT ADMUD ADNMO AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFPUW AFRHN AFTJW AFXIZ AGHFR AGQPQ AGUBO AGYEJ AHMBA AI. AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKEYQ BKOJK BLXMC BNPGV BPHCQ BVXVI CS3 EBS EFJIC EFKBS EFLBG EJD EMOBN EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-Q GBLVA HVGLF HZ~ IHE J1W J5H K-O KOM L7B M41 MO0 N4W N9A O-L O9- OAUVE OF- OPF OQ~ OZT P-8 P-9 P2P PC. PQQKQ PROAC Q38 R2- ROL RPZ SCC SDF SDG SDP SEL SES SPCBC SSH SSZ SV3 T5K UNMZH UV1 VH1 WH7 WOW X7M XPP Z5R ZGI ZXP ~G- ~HD 3V. 7RV 7X7 8FI AACTN AAIAV ABLVK ABYKQ AFCTW AFKRA AFKWA AHPSJ AJBFU AJOXV AMFUW AZQEC BENPR FYUFA G8K GUQSH LCYCR M1P M2O RIG ZA5 9DU AAYXX CITATION AGCQF AGRNS CGR CUY CVF ECM EIF NPM K9. NAPCQ 7X8 5PM |
| ID | FETCH-LOGICAL-c529t-98a45d6ecdd3fb8ff5b60168ac27f149fe4135348cb2c4047a0b9afed2336b0d3 |
| ISICitedReferencesCount | 15 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000810517200005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0002-9394 1879-1891 |
| IngestDate | Tue Sep 30 17:12:25 EDT 2025 Sun Nov 09 13:40:41 EST 2025 Mon Oct 06 18:27:17 EDT 2025 Mon Jul 21 05:55:42 EDT 2025 Sat Nov 29 07:32:19 EST 2025 Tue Nov 18 21:22:31 EST 2025 Fri Feb 23 02:39:51 EST 2024 Tue Oct 14 19:35:28 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Intra-arterial Cytoreductive Chemotherapy (IACC) Disease-free survival Bimodal therapy Neoadjuvant Lacrimal gland adenoid cystic carcinoma (LGACC) Adjuvant Exenteration Lacrimal artery Lateral orbitotomy Globe-sparing surgery Trimodal therapy |
| Language | English |
| License | Copyright © 2022 Elsevier Inc. All rights reserved. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c529t-98a45d6ecdd3fb8ff5b60168ac27f149fe4135348cb2c4047a0b9afed2336b0d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-2270-9219 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/9396917 |
| PMID | 35381201 |
| PQID | 2691438240 |
| PQPubID | 41749 |
| PageCount | 13 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_9396917 proquest_miscellaneous_2647654238 proquest_journals_2691438240 pubmed_primary_35381201 crossref_primary_10_1016_j_ajo_2022_03_027 crossref_citationtrail_10_1016_j_ajo_2022_03_027 elsevier_sciencedirect_doi_10_1016_j_ajo_2022_03_027 elsevier_clinicalkey_doi_10_1016_j_ajo_2022_03_027 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-08-01 |
| PublicationDateYYYYMMDD | 2022-08-01 |
| PublicationDate_xml | – month: 08 year: 2022 text: 2022-08-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Chicago |
| PublicationTitle | American journal of ophthalmology |
| PublicationTitleAlternate | Am J Ophthalmol |
| PublicationYear | 2022 |
| Publisher | Elsevier Inc Elsevier Limited |
| Publisher_xml | – name: Elsevier Inc – name: Elsevier Limited |
| References | Wright, Stewart, Krohel (bib0006) 1979; 63 Tse, Kossler, Feuer, Benedetto (bib0035) 2014; 121 Polito, Leccisotti (bib0022) 1993; 25 Chaney, Sancar (bib0029) 1996; 88 Lee, Campbell, Waller, Ilstrup (bib0001) 1985; 92 Henderson (bib0009) 1986; 70 Wright, Rose, Garner (bib0025) 1992; 76 Jakobiec (bib0021) 1987; 85 Ahmad, Esmaeli, Williams (bib0045) 2009; 116 Zimmerman, Sanders, Ackerman (bib0024) 1962; 2 Henderson, Neault (bib0013) 1976; 82 Rootman, Lapointe (bib0014) 1988 Naugle, Tepper, Haik (bib0010) 1994; 10 Meldrum, Tse, Benedetto (bib0027) 1998; 116 Hanrahan, Shah (bib0047) 2011; 197 Rose, Gore, Plowman (bib0019) 2019; 35 Doddapaneni, Tao, Naranjo, Nikpoor, Tse, Pelaez (bib0051) 2019; 10 Wright (bib0008) 1982; 17 Metzger, Leichman, Danenberg (bib0031) 1998; 16 Yeh, Ramaswamy (bib0050) 2015; 75 Edge, Byrd, Compton (bib0036) 2009 Esmaeli, Golio, Kies, DeMonte (bib0018) 2006; 22 Tse, Kossler, Feuer, Benedetto (bib0033) 2013; 120 Veth, Schreuder, van Beem (bib0049) 2005; 6 Peto, Pike, Armitage (bib0039) 1977; 35 Esmaeli, Ahmadi, Youssef (bib0017) 2004; 20 Li, Xu, Zhao (bib0044) 2012; 118 Marsh, Wise, Smith, Schwartz (bib0015) 1981; 68 Steele, Brewster (bib0038) 2011; 343 Ni, Cheng, Dryja, Cheng (bib0011) 1982; 22 Ashton (bib0023) 1975; 14 Janecka, Housepian, Trokel (bib0016) 1984; 148 Henderson (bib0020) 1987; 85 Han, Kim, Woo, Sobti (bib0041) 2018; 34 Galluzzi, Senovilla, Vitale (bib0028) 2012; 31 Bradley, Bradley (bib0026) 2022; 120 Furuta, Ueda, Aune, Sarasin, Kraemer, Pommier (bib0030) 2002; 62 Font, Smith, Bryan (bib0002) 1998; 116 Byers, Berkeley, Luna, Jesse (bib0012) 1975; 79 Wolkow, Jakobiec, Lee, Sutula (bib0040) 2018; 195 Byers, Berkeley, Luna, Jesse (bib0007) 1975; 79 Penston (bib0037) 2011; 343 Tse, Benedetto, Morcos, Johnson, Weed, Dubovy (bib0042) 2006; 141 Meller, Weinbroum, Bickels (bib0048) 2008; 34 Tse, Benedetto, Dubovy, Schiffman, Feuer (bib0034) 2006; 141 Font, Gamel (bib0003) 1978 Gamel, Font (bib0005) 1982; 13 Font, Gamel (bib0004) 1980 Naugle (10.1016/j.ajo.2022.03.027_bib0010) 1994; 10 Byers (10.1016/j.ajo.2022.03.027_bib0012) 1975; 79 Veth (10.1016/j.ajo.2022.03.027_bib0049) 2005; 6 Chaney (10.1016/j.ajo.2022.03.027_bib0029) 1996; 88 Edge (10.1016/j.ajo.2022.03.027_bib0036) 2009 Penston (10.1016/j.ajo.2022.03.027_bib0037) 2011; 343 Henderson (10.1016/j.ajo.2022.03.027_bib0013) 1976; 82 Henderson (10.1016/j.ajo.2022.03.027_bib0020) 1987; 85 Janecka (10.1016/j.ajo.2022.03.027_bib0016) 1984; 148 Henderson (10.1016/j.ajo.2022.03.027_bib0009) 1986; 70 Meldrum (10.1016/j.ajo.2022.03.027_bib0027) 1998; 116 Tse (10.1016/j.ajo.2022.03.027_bib0034) 2006; 141 Ahmad (10.1016/j.ajo.2022.03.027_bib0045) 2009; 116 Gamel (10.1016/j.ajo.2022.03.027_bib0005) 1982; 13 Rootman (10.1016/j.ajo.2022.03.027_bib0014) 1988 Hanrahan (10.1016/j.ajo.2022.03.027_bib0047) 2011; 197 Byers (10.1016/j.ajo.2022.03.027_bib0007) 1975; 79 Jakobiec (10.1016/j.ajo.2022.03.027_bib0021) 1987; 85 Wright (10.1016/j.ajo.2022.03.027_bib0025) 1992; 76 Wolkow (10.1016/j.ajo.2022.03.027_bib0040) 2018; 195 Marsh (10.1016/j.ajo.2022.03.027_bib0015) 1981; 68 Zimmerman (10.1016/j.ajo.2022.03.027_bib0024) 1962; 2 Wright (10.1016/j.ajo.2022.03.027_bib0008) 1982; 17 Meller (10.1016/j.ajo.2022.03.027_bib0048) 2008; 34 Esmaeli (10.1016/j.ajo.2022.03.027_bib0017) 2004; 20 Han (10.1016/j.ajo.2022.03.027_bib0041) 2018; 34 Li (10.1016/j.ajo.2022.03.027_bib0044) 2012; 118 Ni (10.1016/j.ajo.2022.03.027_bib0011) 1982; 22 Yeh (10.1016/j.ajo.2022.03.027_bib0050) 2015; 75 Rose (10.1016/j.ajo.2022.03.027_bib0019) 2019; 35 Esmaeli (10.1016/j.ajo.2022.03.027_bib0018) 2006; 22 Tse (10.1016/j.ajo.2022.03.027_bib0033) 2013; 120 Font (10.1016/j.ajo.2022.03.027_bib0002) 1998; 116 Steele (10.1016/j.ajo.2022.03.027_bib0038) 2011; 343 Peto (10.1016/j.ajo.2022.03.027_bib0039) 1977; 35 Font (10.1016/j.ajo.2022.03.027_bib0003) 1978 Tse (10.1016/j.ajo.2022.03.027_bib0042) 2006; 141 Font (10.1016/j.ajo.2022.03.027_bib0004) 1980 Doddapaneni (10.1016/j.ajo.2022.03.027_bib0051) 2019; 10 Galluzzi (10.1016/j.ajo.2022.03.027_bib0028) 2012; 31 Furuta (10.1016/j.ajo.2022.03.027_bib0030) 2002; 62 Polito (10.1016/j.ajo.2022.03.027_bib0022) 1993; 25 Lee (10.1016/j.ajo.2022.03.027_bib0001) 1985; 92 Wright (10.1016/j.ajo.2022.03.027_bib0006) 1979; 63 Metzger (10.1016/j.ajo.2022.03.027_bib0031) 1998; 16 Ashton (10.1016/j.ajo.2022.03.027_bib0023) 1975; 14 Bradley (10.1016/j.ajo.2022.03.027_bib0026) 2022; 120 Tse (10.1016/j.ajo.2022.03.027_bib0035) 2014; 121 |
| References_xml | – volume: 116 start-page: 315 year: 1998 end-page: 321 ident: bib0027 article-title: Neoadjuvant intracarotid chemotherapy for treatment of advanced adenocystic carcinoma of the lacrimal gland publication-title: Arch Ophthalmol – volume: 62 start-page: 4899 year: 2002 end-page: 4902 ident: bib0030 article-title: Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells publication-title: Cancer Res – volume: 148 start-page: 539 year: 1984 end-page: 541 ident: bib0016 article-title: Surgical management of malignant tumors of the lacrimal gland publication-title: Am J Surg – volume: 35 start-page: 1 year: 1977 end-page: 39 ident: bib0039 article-title: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples publication-title: Br J Cancer – volume: 17 start-page: 3 year: 1982 end-page: 9 ident: bib0008 article-title: Factors affecting the survival of patients with lacrimal gland tumours publication-title: Can J Ophthalmol – volume: 116 start-page: 613 year: 1998 end-page: 616 ident: bib0002 article-title: Malignant epithelial tumors of the lacrimal gland: a clinicopathologic study of 21 cases publication-title: Arch Ophthalmol – volume: 13 start-page: 219 year: 1982 end-page: 225 ident: bib0005 article-title: Adenoid cystic carcinoma of the lacrimal gland: the clinical significance of a basaloid histologic pattern publication-title: Hum Pathol – start-page: 569 year: 2009 end-page: 571 ident: bib0036 article-title: AJCC Cancer Staging Manual – volume: 6 start-page: 25 year: 2005 end-page: 34 ident: bib0049 article-title: Cryosurgery in aggressive, benign, and low-grade malignant bone tumours publication-title: Lancet Oncol – volume: 343 start-page: 2091 year: 2011 end-page: d6397 ident: bib0038 article-title: Should we use total mortality rather than cancer-specific mortality to judge cancer screening programmes? publication-title: BMJ – volume: 197 start-page: 1309 year: 2011 end-page: 1321 ident: bib0047 article-title: MRI of spinal bone marrow: Part 2, T1-weighted imaging-based differential diagnosis publication-title: AJR – volume: 35 start-page: 77 year: 2019 end-page: 84 ident: bib0019 article-title: Cranio-orbital resection does not appear to improve survival of patients with lacrimal gland carcinoma publication-title: Ophthal Plast Reconstr Surg – volume: 2 start-page: 337 year: 1962 end-page: 367 ident: bib0024 article-title: Epithelial tumors of the lacrimal gland: prognostic and therapeutic significance of histologic types publication-title: Int Ophthalmol Clin – volume: 85 start-page: 312 year: 1987 end-page: 314 ident: bib0020 article-title: Adenoid cystic carcinoma of the lacrimal gland, is there a cure? publication-title: Trans Am Ophthalmol Soc – volume: 22 start-page: 366 year: 2006 end-page: 370 ident: bib0018 article-title: Surgical management of locally advanced adenoid cystic carcinoma of the lacrimal gland publication-title: Ophthal Plast Reconstr Surg – volume: 343 start-page: 1008 year: 2011 end-page: d6395 ident: bib0037 article-title: Should we use total mortality rather than cancer-specific mortality to judge cancer screening programmes? Yes publication-title: BMJ – volume: 31 start-page: 1869 year: 2012 end-page: 1883 ident: bib0028 article-title: Molecular mechanisms of cisplatin resistance publication-title: Oncogene – volume: 34 start-page: 74 year: 2018 end-page: 78 ident: bib0041 article-title: Long-term outcomes of eye-sparing surgery for adenoid cystic carcinoma of lacrimal gland, ophthalmic plastic and reconstructive surgery publication-title: Ophthalmic Plast Reconstructr Surg – volume: 16 start-page: 309 year: 1998 end-page: 316 ident: bib0031 article-title: ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy publication-title: J Clin Oncol – volume: 118 start-page: 3945 year: 2012 end-page: 3953 ident: bib0044 article-title: A comparison of the demographics, clinical features, and survival of patients with adenoid cystic carcinoma of major and minor salivary glands versus less common sites within the Surveillance, Epidemiology, and End Results registry publication-title: Cancer – volume: 82 start-page: 905 year: 1976 end-page: 909 ident: bib0013 article-title: En bloc removal of intrinsic neoplasms of the lacrimal gland publication-title: Am J Ophthalmol – volume: 92 start-page: 128 year: 1985 end-page: 134 ident: bib0001 article-title: A clinicopathologic study of primary adenoid cystic carcinoma of the lacrimal gland publication-title: Ophthalmology – volume: 25 start-page: 422 year: 1993 end-page: 426 ident: bib0022 article-title: Epithelial malignancies of the lacrimal gland: survival rates after extensive and conservative therapy publication-title: Ann Ophthalmol – volume: 22 start-page: 99 year: 1982 end-page: 120 ident: bib0011 article-title: Lacrimal gland tumors: a clinicopathological analysis of 160 cases publication-title: Int Ophthalmol Clin – volume: 14 start-page: 306 year: 1975 end-page: 323 ident: bib0023 article-title: Epithelial tumours of the lacrimal gland publication-title: Mod Probl Ophthalmol – volume: 70 start-page: 727 year: 1986 end-page: 731 ident: bib0009 article-title: Past, present, and future surgical management of malignant epithelial neoplasms of the lacrimal gland publication-title: Br J Ophthalmol – volume: 120 start-page: 1313 year: 2013 end-page: 1323 ident: bib0033 article-title: Long-term outcomes of neoadjuvant intra-arterial cytoreductive chemotherapy for lacrimal gland adenoid cystic carcinoma publication-title: Ophthalmology – start-page: 787 year: 1978 end-page: 805 ident: bib0003 article-title: Epithelial tumors of the lacrimal gland: an analysis of 265 cases publication-title: Ocular and Adnexal Tumors – volume: 34 start-page: 921 year: 2008 end-page: 927 ident: bib0048 article-title: Fifteen years of bone cryosurgery: A single-center experience of 440 procedures and long-term follow-up publication-title: Eur J Surg Oncol – volume: 79 start-page: 53 year: 1975 end-page: 55 ident: bib0012 article-title: Combined therapeutic approach to malignant lacrimal gland tumors publication-title: Am J Ophthalmol – volume: 116 start-page: 1210 year: 2009 end-page: 1215 ident: bib0045 article-title: American Joint Committee on Cancer classification predicts outcome of patients with lacrimal-gland adenoid cystic carcinoma publication-title: Ophthalmology – volume: 120 start-page: 1311 year: 2022 end-page: 1312 ident: bib0026 article-title: Adenoid Cystic Carcinoma of the Lacrimal Gland: Rare . . . Lethal . . . Cured? publication-title: Ophthalmology – volume: 10 start-page: 480 year: 2019 end-page: 493 ident: bib0051 article-title: Fibroblast growth factor receptor 1 (FGFR1) as a therapeutic target in adenoid cystic carcinoma of the lacrimal gland publication-title: Oncotarget – volume: 68 start-page: 577 year: 1981 end-page: 585 ident: bib0015 article-title: Lacrimal gland adenoid cystic carcinoma: intracranial and extracranial en bloc resection publication-title: Plast Reconstr Surg – volume: 195 start-page: 43 year: 2018 end-page: 62 ident: bib0040 article-title: Long-term outcomes of globe-preserving surgery with proton beam radiation for adenoid cystic carcinoma of the lacrimal gland publication-title: Am J Ophthalmol – volume: 141 start-page: 44 year: 2006 end-page: 53 ident: bib0034 article-title: Clinical analysis of the effect of intraarterial cytoreductive chemotherapy in the treatment of lacrimal gland adenoid cystic carcinoma publication-title: Am J Ophthalmol – start-page: 384 year: 1988 end-page: 395 ident: bib0014 article-title: Tumors of the lacrimal gland publication-title: Diseases of the Orbit; A Multidisciplinary Approach – volume: 121 start-page: e8 year: 2014 end-page: e10 ident: bib0035 article-title: Author reply: To PMID 23582989 publication-title: Ophthalmology – volume: 75 start-page: 5014 year: 2015 end-page: 5022 ident: bib0050 article-title: Mechanisms of cancer cell dormancy – another hallmark of cancer? publication-title: Cancer Res – volume: 141 start-page: 187 year: 2006 end-page: 189 ident: bib0042 article-title: An atypical presentation of adenoid cystic carcinoma of the lacrimal gland publication-title: Am J Ophthalmol – volume: 85 start-page: 314 year: 1987 end-page: 317 ident: bib0021 article-title: Discussion of Henderson JW. Adenoid cystic carcinoma of the lacrimal gland: is there a cure? publication-title: Trans Am Ophthalmol Soc – volume: 76 start-page: 401 year: 1992 end-page: 407 ident: bib0025 article-title: Primary malignant neoplasms of the lacrimal gland publication-title: Br J Ophthalmol – volume: 79 start-page: 53 year: 1975 end-page: 55 ident: bib0007 article-title: Combined therapeutic approach to malignant lacrimal gland tumors publication-title: Am J Ophthalmol – volume: 10 start-page: 45 year: 1994 end-page: 48 ident: bib0010 article-title: Adenoid cystic carcinoma of the lacrimal gland: a case report publication-title: Ophthalmic Plast Reconstr Surg – volume: 63 year: 1979 ident: bib0006 article-title: Clinical presentation and management of lacrimal gland tumours publication-title: Br J Ophthalmol – volume: 20 start-page: 22 year: 2004 end-page: 26 ident: bib0017 article-title: Outcomes in patients with adenoid cystic carcinoma of the lacrimal gland publication-title: Ophthal Plast Reconstr Surg – volume: 88 start-page: 1346 year: 1996 end-page: 1360 ident: bib0029 article-title: DNA repair: enzymatic mechanisms and relevance to drug response publication-title: J Natl Cancer Inst – start-page: 277 year: 1980 end-page: 283 ident: bib0004 article-title: Adenoid cystic carcinoma of the lacrimal gland. A clinicopathologic study of 79 cases publication-title: . Update – volume: 25 start-page: 422 year: 1993 ident: 10.1016/j.ajo.2022.03.027_bib0022 article-title: Epithelial malignancies of the lacrimal gland: survival rates after extensive and conservative therapy publication-title: Ann Ophthalmol – start-page: 277 year: 1980 ident: 10.1016/j.ajo.2022.03.027_bib0004 article-title: Adenoid cystic carcinoma of the lacrimal gland. A clinicopathologic study of 79 cases – volume: 116 start-page: 315 year: 1998 ident: 10.1016/j.ajo.2022.03.027_bib0027 article-title: Neoadjuvant intracarotid chemotherapy for treatment of advanced adenocystic carcinoma of the lacrimal gland publication-title: Arch Ophthalmol doi: 10.1001/archopht.116.3.315 – start-page: 569 year: 2009 ident: 10.1016/j.ajo.2022.03.027_bib0036 – volume: 116 start-page: 1210 year: 2009 ident: 10.1016/j.ajo.2022.03.027_bib0045 article-title: American Joint Committee on Cancer classification predicts outcome of patients with lacrimal-gland adenoid cystic carcinoma publication-title: Ophthalmology doi: 10.1016/j.ophtha.2008.12.049 – volume: 13 start-page: 219 issue: 3 year: 1982 ident: 10.1016/j.ajo.2022.03.027_bib0005 article-title: Adenoid cystic carcinoma of the lacrimal gland: the clinical significance of a basaloid histologic pattern publication-title: Hum Pathol doi: 10.1016/S0046-8177(82)80180-9 – volume: 35 start-page: 1 issue: 1 year: 1977 ident: 10.1016/j.ajo.2022.03.027_bib0039 article-title: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples publication-title: Br J Cancer doi: 10.1038/bjc.1977.1 – volume: 10 start-page: 480 issue: 4 year: 2019 ident: 10.1016/j.ajo.2022.03.027_bib0051 article-title: Fibroblast growth factor receptor 1 (FGFR1) as a therapeutic target in adenoid cystic carcinoma of the lacrimal gland publication-title: Oncotarget doi: 10.18632/oncotarget.26558 – start-page: 787 year: 1978 ident: 10.1016/j.ajo.2022.03.027_bib0003 article-title: Epithelial tumors of the lacrimal gland: an analysis of 265 cases – volume: 22 start-page: 99 year: 1982 ident: 10.1016/j.ajo.2022.03.027_bib0011 article-title: Lacrimal gland tumors: a clinicopathological analysis of 160 cases publication-title: Int Ophthalmol Clin doi: 10.1097/00004397-198202210-00009 – volume: 75 start-page: 5014 issue: 23 year: 2015 ident: 10.1016/j.ajo.2022.03.027_bib0050 article-title: Mechanisms of cancer cell dormancy – another hallmark of cancer? publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-15-1370 – volume: 6 start-page: 25 year: 2005 ident: 10.1016/j.ajo.2022.03.027_bib0049 article-title: Cryosurgery in aggressive, benign, and low-grade malignant bone tumours publication-title: Lancet Oncol doi: 10.1016/S1470-2045(05)70023-1 – volume: 148 start-page: 539 year: 1984 ident: 10.1016/j.ajo.2022.03.027_bib0016 article-title: Surgical management of malignant tumors of the lacrimal gland publication-title: Am J Surg doi: 10.1016/0002-9610(84)90384-2 – volume: 120 start-page: 1311 year: 2022 ident: 10.1016/j.ajo.2022.03.027_bib0026 article-title: Adenoid Cystic Carcinoma of the Lacrimal Gland: Rare . . . Lethal . . . Cured? publication-title: Ophthalmology doi: 10.1016/j.ophtha.2013.05.006 – volume: 141 start-page: 187 year: 2006 ident: 10.1016/j.ajo.2022.03.027_bib0042 article-title: An atypical presentation of adenoid cystic carcinoma of the lacrimal gland publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2005.08.070 – volume: 85 start-page: 312 year: 1987 ident: 10.1016/j.ajo.2022.03.027_bib0020 article-title: Adenoid cystic carcinoma of the lacrimal gland, is there a cure? publication-title: Trans Am Ophthalmol Soc – volume: 141 start-page: 44 issue: 1 year: 2006 ident: 10.1016/j.ajo.2022.03.027_bib0034 article-title: Clinical analysis of the effect of intraarterial cytoreductive chemotherapy in the treatment of lacrimal gland adenoid cystic carcinoma publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2005.08.068 – volume: 116 start-page: 613 year: 1998 ident: 10.1016/j.ajo.2022.03.027_bib0002 article-title: Malignant epithelial tumors of the lacrimal gland: a clinicopathologic study of 21 cases publication-title: Arch Ophthalmol doi: 10.1001/archopht.116.5.613 – volume: 17 start-page: 3 issue: 1 year: 1982 ident: 10.1016/j.ajo.2022.03.027_bib0008 article-title: Factors affecting the survival of patients with lacrimal gland tumours publication-title: Can J Ophthalmol – volume: 85 start-page: 314 year: 1987 ident: 10.1016/j.ajo.2022.03.027_bib0021 article-title: Discussion of Henderson JW. Adenoid cystic carcinoma of the lacrimal gland: is there a cure? publication-title: Trans Am Ophthalmol Soc – volume: 79 start-page: 53 year: 1975 ident: 10.1016/j.ajo.2022.03.027_bib0012 article-title: Combined therapeutic approach to malignant lacrimal gland tumors publication-title: Am J Ophthalmol doi: 10.1016/0002-9394(75)90455-9 – volume: 20 start-page: 22 year: 2004 ident: 10.1016/j.ajo.2022.03.027_bib0017 article-title: Outcomes in patients with adenoid cystic carcinoma of the lacrimal gland publication-title: Ophthal Plast Reconstr Surg doi: 10.1097/01.IOP.0000105518.72611.4F – volume: 62 start-page: 4899 year: 2002 ident: 10.1016/j.ajo.2022.03.027_bib0030 article-title: Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells publication-title: Cancer Res – volume: 14 start-page: 306 year: 1975 ident: 10.1016/j.ajo.2022.03.027_bib0023 article-title: Epithelial tumours of the lacrimal gland publication-title: Mod Probl Ophthalmol – volume: 121 start-page: e8 issue: 1 year: 2014 ident: 10.1016/j.ajo.2022.03.027_bib0035 article-title: Author reply: To PMID 23582989 publication-title: Ophthalmology doi: 10.1016/j.ophtha.2013.11.012 – volume: 82 start-page: 905 year: 1976 ident: 10.1016/j.ajo.2022.03.027_bib0013 article-title: En bloc removal of intrinsic neoplasms of the lacrimal gland publication-title: Am J Ophthalmol doi: 10.1016/0002-9394(76)90068-4 – volume: 343 start-page: 1008 year: 2011 ident: 10.1016/j.ajo.2022.03.027_bib0037 article-title: Should we use total mortality rather than cancer-specific mortality to judge cancer screening programmes? Yes publication-title: BMJ doi: 10.1136/bmj.d6395 – volume: 2 start-page: 337 year: 1962 ident: 10.1016/j.ajo.2022.03.027_bib0024 article-title: Epithelial tumors of the lacrimal gland: prognostic and therapeutic significance of histologic types publication-title: Int Ophthalmol Clin doi: 10.1097/00004397-196206000-00005 – volume: 76 start-page: 401 year: 1992 ident: 10.1016/j.ajo.2022.03.027_bib0025 article-title: Primary malignant neoplasms of the lacrimal gland publication-title: Br J Ophthalmol doi: 10.1136/bjo.76.7.401 – volume: 118 start-page: 3945 year: 2012 ident: 10.1016/j.ajo.2022.03.027_bib0044 article-title: A comparison of the demographics, clinical features, and survival of patients with adenoid cystic carcinoma of major and minor salivary glands versus less common sites within the Surveillance, Epidemiology, and End Results registry publication-title: Cancer doi: 10.1002/cncr.26740 – volume: 197 start-page: 1309 year: 2011 ident: 10.1016/j.ajo.2022.03.027_bib0047 article-title: MRI of spinal bone marrow: Part 2, T1-weighted imaging-based differential diagnosis publication-title: AJR doi: 10.2214/AJR.11.7420 – volume: 22 start-page: 366 issue: 5 year: 2006 ident: 10.1016/j.ajo.2022.03.027_bib0018 article-title: Surgical management of locally advanced adenoid cystic carcinoma of the lacrimal gland publication-title: Ophthal Plast Reconstr Surg doi: 10.1097/01.iop.0000232164.00208.b4 – volume: 195 start-page: 43 year: 2018 ident: 10.1016/j.ajo.2022.03.027_bib0040 article-title: Long-term outcomes of globe-preserving surgery with proton beam radiation for adenoid cystic carcinoma of the lacrimal gland publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2018.07.024 – volume: 34 start-page: 921 year: 2008 ident: 10.1016/j.ajo.2022.03.027_bib0048 article-title: Fifteen years of bone cryosurgery: A single-center experience of 440 procedures and long-term follow-up publication-title: Eur J Surg Oncol doi: 10.1016/j.ejso.2007.11.001 – volume: 34 start-page: 74 issue: 1 year: 2018 ident: 10.1016/j.ajo.2022.03.027_bib0041 article-title: Long-term outcomes of eye-sparing surgery for adenoid cystic carcinoma of lacrimal gland, ophthalmic plastic and reconstructive surgery publication-title: Ophthalmic Plast Reconstructr Surg doi: 10.1097/IOP.0000000000000877 – volume: 68 start-page: 577 year: 1981 ident: 10.1016/j.ajo.2022.03.027_bib0015 article-title: Lacrimal gland adenoid cystic carcinoma: intracranial and extracranial en bloc resection publication-title: Plast Reconstr Surg doi: 10.1097/00006534-198110000-00017 – volume: 88 start-page: 1346 year: 1996 ident: 10.1016/j.ajo.2022.03.027_bib0029 article-title: DNA repair: enzymatic mechanisms and relevance to drug response publication-title: J Natl Cancer Inst doi: 10.1093/jnci/88.19.1346 – volume: 70 start-page: 727 year: 1986 ident: 10.1016/j.ajo.2022.03.027_bib0009 article-title: Past, present, and future surgical management of malignant epithelial neoplasms of the lacrimal gland publication-title: Br J Ophthalmol doi: 10.1136/bjo.70.10.727 – volume: 92 start-page: 128 issue: 1 year: 1985 ident: 10.1016/j.ajo.2022.03.027_bib0001 article-title: A clinicopathologic study of primary adenoid cystic carcinoma of the lacrimal gland publication-title: Ophthalmology doi: 10.1016/S0161-6420(85)34081-2 – volume: 79 start-page: 53 issue: 1 year: 1975 ident: 10.1016/j.ajo.2022.03.027_bib0007 article-title: Combined therapeutic approach to malignant lacrimal gland tumors publication-title: Am J Ophthalmol doi: 10.1016/0002-9394(75)90455-9 – volume: 35 start-page: 77 year: 2019 ident: 10.1016/j.ajo.2022.03.027_bib0019 article-title: Cranio-orbital resection does not appear to improve survival of patients with lacrimal gland carcinoma publication-title: Ophthal Plast Reconstr Surg doi: 10.1097/IOP.0000000000001177 – volume: 31 start-page: 1869 year: 2012 ident: 10.1016/j.ajo.2022.03.027_bib0028 article-title: Molecular mechanisms of cisplatin resistance publication-title: Oncogene doi: 10.1038/onc.2011.384 – volume: 120 start-page: 1313 year: 2013 ident: 10.1016/j.ajo.2022.03.027_bib0033 article-title: Long-term outcomes of neoadjuvant intra-arterial cytoreductive chemotherapy for lacrimal gland adenoid cystic carcinoma publication-title: Ophthalmology doi: 10.1016/j.ophtha.2013.01.027 – start-page: 384 year: 1988 ident: 10.1016/j.ajo.2022.03.027_bib0014 article-title: Tumors of the lacrimal gland – volume: 16 start-page: 309 year: 1998 ident: 10.1016/j.ajo.2022.03.027_bib0031 article-title: ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy publication-title: J Clin Oncol doi: 10.1200/JCO.1998.16.1.309 – volume: 10 start-page: 45 year: 1994 ident: 10.1016/j.ajo.2022.03.027_bib0010 article-title: Adenoid cystic carcinoma of the lacrimal gland: a case report publication-title: Ophthalmic Plast Reconstr Surg doi: 10.1097/00002341-199403000-00009 – volume: 343 start-page: 2091 year: 2011 ident: 10.1016/j.ajo.2022.03.027_bib0038 article-title: Should we use total mortality rather than cancer-specific mortality to judge cancer screening programmes? publication-title: BMJ doi: 10.1136/bmj.d6397 – volume: 63 issue: 9 year: 1979 ident: 10.1016/j.ajo.2022.03.027_bib0006 article-title: Clinical presentation and management of lacrimal gland tumours publication-title: Br J Ophthalmol doi: 10.1136/bjo.63.9.600 |
| SSID | ssj0006747 |
| Score | 2.4743495 |
| Snippet | To report the therapeutic efficacy of integrating neoadjuvant chemotherapy with conventional bimodal therapies for lacrimal gland adenoid cystic carcinoma by... PurposeTo report the therapeutic efficacy of integrating neoadjuvant chemotherapy with conventional bimodal therapies for lacrimal gland adenoid cystic... |
| SourceID | pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 239 |
| SubjectTerms | Adjuvant Bimodal therapy Cancer therapies Carcinoma, Adenoid Cystic - drug therapy Carotid arteries Chemotherapy Cytoreduction Surgical Procedures Disease control Disease-free survival Exenteration Exocrine glands Eye Neoplasms - drug therapy Eye Neoplasms - pathology Follow-Up Studies Globe-sparing surgery Head and Neck Neoplasms Humans Intra-arterial Cytoreductive Chemotherapy (IACC) Lacrimal Apparatus - pathology Lacrimal Apparatus Diseases - drug therapy Lacrimal Apparatus Diseases - pathology Lacrimal artery Lacrimal gland adenoid cystic carcinoma (LGACC) Lateral orbitotomy Margins of Excision Metastasis Mortality Neoadjuvant Neoadjuvant Therapy Neoplasm Recurrence, Local Patients Radiation therapy Retrospective Studies Trimodal therapy Veins & arteries |
| Title | Neoadjuvant Intra-Arterial Cytoreductive Chemotherapy for Lacrimal Gland Adenoid Cystic Carcinoma: A Long-Term Follow-up Study of a Trimodal Strategy |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0002939422001362 https://dx.doi.org/10.1016/j.ajo.2022.03.027 https://www.ncbi.nlm.nih.gov/pubmed/35381201 https://www.proquest.com/docview/2691438240 https://www.proquest.com/docview/2647654238 https://pubmed.ncbi.nlm.nih.gov/PMC9396917 |
| Volume | 240 |
| WOSCitedRecordID | wos000810517200005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: ScienceDirect customDbUrl: eissn: 1879-1891 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0006747 issn: 0002-9394 databaseCode: AIEXJ dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3bbtNAEF2VFiFeEHcCpVoknogcOWsnu-YtVC1QlQqJIPJmrdfrNlFqR2lS2g_h7_gYZrwX4lSUi8SLFdne-DLHszOzM2cIeQlzBFciUwHLwDeJuUgCCbAIukWPSc1lHtlmE_zoSIxGyceNje-uFuZ8ystSXFwks_8qatgHwsbS2b8Qt_9T2AG_QeiwBbHD9o8Ef6QrmU-WYCEvMN43l8EA0zYxMr57CR42crXW-ULIFWDrr0zW5qFUyD0xbb_FdMf2AFRSNc5hFHI5Y2qIGpfVqTTF7IdVeRwMQa-39wFK1ddgOauTEi9NxeUQ_qnKZb3sjWQUjdVjv0y0wltRzU4WJ3J62gjzD03bxzrxvj3s-NgBKOhcL-oOUGADn2FlqG5_6awNezNH7bXrd-_rpQGoDTK1DzqrQQ_wl13KnY3EuWqcRrJord2TyDRN7mij0AVPgq4wHcGcxmeGIcrpbMOmZKd_Zvhvr8wsJsgx6cgJlowyVlPjGlqDNcLuT3gfeBuM1Yx4YCBsMd5LxCbZGrzfGx14S6HPY-7cMxzgVt3r_MO1C_3KbrrqF62n967YS8O75I51dOjAAPQe2dDlfXLrg03leEC-reCUNnFKGzilqzilgFPqcEprnFKLU2pwSj1OX9MB9SilHqW0RimtCiqpQyl1KH1IPu_vDXffBbZHSKB6LFkEiZBxL-9rledRkYmi6GVIMCSkYrwA77_QMXZ2iYXKmIrDmMswS2ShcxZF_SzMo0dks6xK_YTQLtM6DFWWCV3E4Ndkios-6LGsL1kBU1-LhE4CqbIE-tjHZZq6TMlJCkJLUWhpGKUgtBZ55YfMDHvMdSczJ9bUlUXDRJ4CAq8bFPtB1mY2tvDvhm073KT2Uz9LWT_pYl5AHLbIC38YphtcQ5SlrpZ4Tsyxx10Er-OxgZl_MnjP4C6E3RbhDQD6E5DKvnmkHJ_UlPaAfrg4f_pvT_OM3P6pJLbJ5mK-1M_JTXW-GJ_Nd8gNPhI79tv7AXUyHF4 |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Neoadjuvant+Intra-Arterial+Cytoreductive+Chemotherapy+for+Lacrimal+Gland+Adenoid+Cystic+Carcinoma%3A+A+Long-Term+Follow-up+Study+of+a+Trimodal+Strategy&rft.jtitle=American+journal+of+ophthalmology&rft.au=Tse%2C+David+T.&rft.au=Benedetto%2C+Pasquale+W.&rft.au=Tse%2C+Brian+C.&rft.au=Feuer%2C+William+J.&rft.date=2022-08-01&rft.pub=Elsevier+Inc&rft.issn=0002-9394&rft.eissn=1879-1891&rft.volume=240&rft.spage=239&rft.epage=251&rft_id=info:doi/10.1016%2Fj.ajo.2022.03.027&rft.externalDocID=S0002939422001362 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0002-9394&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0002-9394&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0002-9394&client=summon |